MedPath

Aging and Frailty Study

Active, not recruiting
Conditions
Effects of Chemotherapy
Frailty
Aging
Interventions
Other: Geriatric Assessments and Frailty Indices
Registration Number
NCT05268991
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.

Detailed Description

Primary Objective: Describe mean and variation of the electronic frailty index-cancer, geriatric measures, patient reported outcomes, and biomarkers of aging of chemotherapy, and their change.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Age 65 years and older
  • Planned to initiate a new chemotherapy regimen
  • Solid tumor malignancy of any stage or lymphoma
  • Any performance status
  • Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
  • Life expectancy of ≥3 months
Exclusion Criteria
  • Initiating biologic, endocrine or immunotherapy only.
  • Hematologic malignancy other than lymphoma.
  • Concurrent radiation therapy.
  • Planned inpatient chemotherapy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
AGE ParticipantsGeriatric Assessments and Frailty IndicesParticipants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting
Primary Outcome Measures
NameTimeMethod
Resiliency Administered Assessments - Change of Short Physical Performance Battery (SPPB)At baseline, 3 months and 6 months after chemotherapy

The SPPB will be used to assess lower extremity physical function (a short walk of 4 meters, timed repeated chair stands and balances tests). Each task is scored ranging from 0-4 (0 = unable to complete; 4 = highest performance level) with the total sum score range from 0-12. Lower scores indicate increased risk of disability, hospitalization and worse survival among older adults with and without cancer.

Change of Electronic Frailty Index and Cancer Score/CategoryAt baseline, 3 months and 6 months after chemotherapy

Measures collected from the resiliency assessments (Short Physical Performance Battery, Grip Strength, Blessed Orientation Memory and Concentration Test) will be used to calculate the Fried Frailty Index (FFI) to assess frailty. Scores will be anchored to the date of each assessment time point (i.e., baseline visit, follow-up visits). Each data element will be scored from 0 to 1 and the mean will be computed to calculate the overall score. Some data elements (e.g., comorbidities) will be coded as absent or present (0 or 1) and some (e.g., body mass index) will be assigned a score that ranges from 0 to 1. The higher score indicates a higher frailty of the participant.

Resiliency Administered Assessments - Change of Grip StrengthAt baseline, 3 months and 6 months after chemotherapy

Grip strength in both hands will be measured using an adjustable, hydraulic grip strength dynamometer. Two trials will be conducted for each hand. Frailty by this criterion is defined by grip strength cutoffs which are dependent upon both gender and body mass index.

Change in Patient Reported Outcomes Measurement - PROMIS 29At baseline, 3 months and 6 months after chemotherapy

Measures collected from this is a 29-item self-reported measure including 4 items each for the following domains: physical function, anxiety, depression, fatigue, sleep disturbance, social function, and pain interference; plus 1 item measuring average pain intensity and cognition. Scoring is based on a 1-5 point Likert scale (1 = very often; 5 = never). Items are summed to create a total score that ranges from 6-30 and lower scores indicate greater self-reported difficulty.

Resiliency Administered Assessments - Change of Blessed Orientation Memory and Concentration Test (BOMC)At baseline, 3 months and 6 months after chemotherapy

A 6 item test that provides a measure of cognition. For items to 1 to 3 the response is either correct (score = 0) or incorrect (score = 1). For items 4 to 6, one point is added for each error (items 4 and 5 maximum error = 2; item 6 maximum error = 5). Maximum score = 28. Participants with scores ≥ 11 will receive further evaluation or intervention as deemed medically appropriate by the treating physician.

Change of Biomarkers of Aging Observed During Study InterventionAt baseline, 3 months and 6 months after chemotherapy

Investigators will measure targeted panels of blood-based biomarkers including but not limited to serum Interleukin-6, tumor necrosis factor receptors, growth differentiating factor 15, and cystatin C.

Number of Incidences of Toxicity - Grades 2 to 5 Related to Standard of Care ChemotherapyUp to 6 months after chemotherapy

Grade 2 to 5 incidences of toxicities will be recorded and measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.

Number of Documented Dose Reductions During ChemotherapyUp to 6 months after chemotherapy

Participants that have the chemotherapy doses reduced during treatment will be documented.

Number of Dose Delays During ChemotherapyUp to 6 months after chemotherapy

Dose delays greater than three days from planned treatment will be documented.

Number of Early Discontinuations of ChemotherapyUp to 6 months after chemotherapy

Participants that have chemotherapy discontinued prior to anticipated completion of treatment will be documented.

Number of Unplanned HospitalizationsUp to 6 months after chemotherapy

Participants that required unplanned hospitalizations will be documented.

Overall SurvivalUp to 6 months after chemotherapy

Participants will be followed after completion of chemotherapy for survival status.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Wake Forest Baptist Comprehensive Cancer Center

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath